2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Tuesday, November 10, 2015

9:00AM-11:00AM: Abstract Number: 2774

Longterm Outcome of Patients Switched from Iv to Sc Formulation of Abatacept: A Monocentric Study

Rheumatoid Arthritis - Small Molecules, Biologics and Gene Therapy Poster III

9:00AM-11:00AM: Abstract Number: 2203

Loss of Wdfy3 Leads to Enhanced Osteoclastogenesis Via NF-κB Activation

Biology and Pathology of Bone and Joint: Bone Remodeling and Metabolism

9:00AM-11:00AM: Abstract Number: 2658

Low Disease Activity Is Associated with Higher HDL and a Trend to Lower Insulin Resistance in Rheumatoid Arthritis Patients

Rheumatoid Arthritis - Clinical Aspects Poster Session III

9:00AM-11:00AM: Abstract Number: 2933

Low Prevalence of PCP in Hospitalized Patients with SLE: Review of a Clinical Database Warehouse

Systemic Lupus Erythematosus - Clinical Aspects and Treatment Poster Session III

9:00AM-11:00AM: Abstract Number: 2921

Lupus Nephritis: An Exploration of Management Style

Systemic Lupus Erythematosus - Clinical Aspects and Treatment Poster Session III

9:00AM-11:00AM: Abstract Number: 2548

M-CSF-R Is a Critical Determinant for the Differentiation of Classical to Non-Classical Monocytes

Rheumatoid Arthritis - Animal Models Poster

9:00AM-11:00AM: Abstract Number: 2424

Macrophage Activation Syndrome in Systemic Juvenile Idiopathic Arthritis Patients Treated with Canakinumab: Results from Phase 3 Trial Program

Pediatric Rheumatology - Clinical and Therapeutic Aspects Posters (ACR): Imaging and Novel Clinical Interventions

9:00AM-11:00AM: Abstract Number: 2208

Macrophage Migration Inhibitory Factor: A Novel Biomarker in Ankylosing Spondylitis That Can Drive Spinal Fusion

Biology and Pathology of Bone and Joint: Bone Remodeling and Metabolism

9:00AM-11:00AM: Abstract Number: 2356

Major Cardiovascular Events in Gout Patients with Cardiovascular Disease or Heart Failure and Chronic Kidney Disease Initiating on Allopurinol or Febuxostat (Uloric)

Metabolic and Crystal Arthropathies Poster II

9:00AM-11:00AM: Abstract Number: 2671

Male Gender and Higher Hemoglobin Predict Response to Methotrexate in Rheumatoid Arthritis

Rheumatoid Arthritis - Clinical Aspects Poster Session III

9:00AM-11:00AM: Abstract Number: 2999

Maternal Microchimerism Is Increased in Multiple Cellular Subsets of Patients with Systemic Sclerosis Compared to Healthy Controls

Systemic Sclerosis, Fibrosing Syndromes and Raynaud's - Pathogenesis, Animal Models and Genetics Poster II

9:00AM-11:00AM: Abstract Number: 2981

Measurement of Tissue Damage in Scleroderma Using Digital Mammographic Xrays: A Proof of Concept Study

Systemic Sclerosis, Fibrosing Syndromes and Raynaud's - Clinical Aspects and Therapeutics Poster III

9:00AM-11:00AM: Abstract Number: 2426

Medication Taper and Risk of Relapse in Pediatric Uveitis

Pediatric Rheumatology - Clinical and Therapeutic Aspects Posters (ACR): Imaging and Novel Clinical Interventions

9:00AM-11:00AM: Abstract Number: 2515

MEK5/ERK5, a Lynchpin of Human Cardiac Fibroblast Transdifferentiation to a Scarring Phenotype in Autoimmune Congenital Heart Block

Reproductive Issues in Rheumatic Disorders: Basic and Clinical Aspects Poster Session

9:00AM-11:00AM: Abstract Number: 2550

Metabolomic Profiling of Joints in Murine Models of Inflammatory Arthritis

Rheumatoid Arthritis - Animal Models Poster

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].